
5

20

30



What is claimed is:

- 1. A method for regulating, controlling or modulating aqueous humor secretion, comprising the step of administering to ciliary epithelial cells of the aqueous humor, an effective secretion-modulating amount of a pharmaceutical composition comprising a modulator of one or more antiports:
- 2. The method of claim 1, wherein the one or more antiports are selected from the group consisting of a Na⁺/H⁺ exchanger and a Cl⁻/HCO₃ exchanger.
- 3. The method of claim 1, wherein the one or more antiports comprise a Na⁺/H⁺ exchanger and a Cl'/HCO₃⁻ exchanger.
 - 4. The method of claims 1-3, wherein secretion in the aqueous humor cells is elevated, and wherein the modulator is administered in an amount, sufficient to reduce the elevated secretion.
- 15 5. A method for regulating, controlling or modulating fluid pressure in aqueous for including the step of administering to said cells an modulating amount of a pharmaceutical composition comprising a modulator of one or more antiports.
 - 6. The method of claim 5, wherein the one or more antiports are selected from the group consisting of a Na⁺/H⁺ exchanger and a Cl/HCO₃ exchanger.
 - 7. The method of claim 5, wherein the one or more antiports comprise a Na[†]/H, exchanger and a Cl/HCO₃ exchanger.
 - 8. The method of claims 5-7, wherein the fluid pressure is elevated, and wherein the modulator is administered in an amount, sufficient to reduce the elevated pressure.
- 25 9. The method of claims 1-8 wherein the Na⁺/H⁺ exchange occurs at the NHE-1 antiport.
 - 10. The method of claims 1-8, wherein the Cl⁻/HCO₃ exchange occurs at the AE2 antiport.
 - 11. The method of claims 1-10, wherein the modulating effect is reversible upon cessation of administration of the modulator.
 - 12. A method for regulating, controlling or modulating fluid pressure in aqueous humor ciliary epithelial cells of an individual, comprising the step of

5

15

30

- amount of a pharmaceutical composition comprising a modulator of one or more antiports.
- 13. The method of claim 12, wherein the one or more antiports are selected from the group consisting of a Na[†]/H[†] exchanger and a Cl[†]/HCO₃[†] exchanger:
- 14. The method of claim 12, wherein the one or more antiports comprise a Na⁺/H⁺ exchanger and a Cl/HCO3 exchanger.
- 15. The method of claims 12-14, wherein the NaT/HT exchanger comprises NHE-1.
- 16. The method of claims 12-14, wherein the Cl/HCO₃ exchanger comprises AE2.
- 17. The method of claims 1-16, wherein the modulator is administered to the cells in 10 vitro.
 - 18. The method of claims 1-16, wherein the modylator is administered to the cells in vivo.
 - 19. A method for regulating, controlling or modulating intraocular pressure in an individual, comprising the step of administering to the individual an effective intraocular pressure modulating amount of a pharmaceutical composition. comprising a modulator of one or more antiports.
 - 20. The method of claim 19, wherein the one or more antiports are selected from the group consisting of a Na⁺/H⁺/exchanger and a Cl⁻/HCO₃ exchanger.
- 21. The method of claim 19, wherein the one or more antiports comprise a Na⁺/H⁺ 20 exchanger and a Cl/HCQ3 exchanger.
 - 22. The method of claim 1/9-21, wherein the intraocular pressure is elevated, and wherein the modulator is administered in an amount, sufficient to reduce the elevated intraocular pressure.
- 23. The method of claims 12-24, wherein the Na⁺/H⁺ exchanger comprises NHE-1. 25
 - 24. The method of claims 12-24, wherein the Cl7/HCO₃ exchanger comprises AE2.
 - 25. The method of claims 12-24, wherein the modulating effect is reversible upon cessation of administration of the modulator.
 - 26. The method of claims 1-25, wherein the modulator comprises a modulator of Na⁺/H/ exchange.
 - 27. The method of claims 1-25/wherein the modulator comprises a modulator of Cl /HCO3 exchange.

5

10

15

- 28. The methods of claims 19-27, wherein the individual suffers from glaucoma.
- 29. The methods of claims 19-27, wherein the individual is subject to glaucoma.
- 30. The method of claims 1-29, wherein the modulator is selected from the group consisting of beta blockers, amilorides and cariporide.
- 31. The method of claim 30, wherein the modulator comprises a beta blocker.
 - 32. The method of claim 31, wherein the beta blocker comprises timilol.
 - 33. The method of claim 30, wherein the modulator comprises an amiloride or amiloride analog.
 - 34. The method of claim 33, wherein the amiloride comprises either amiloride or ethyl-isopropyl-amiloride.
 - 35. The method of claim 30, wherein the modulator comprises cariporide.
 - 36. The method of claims 1, 5, 12 or 19, wherein an anion is transferred into the ciliary epithelial cells of the aqueous humor to block native chloride channels.
 - 37. The method of claim 36, wherein the anion comprises cyclamate.

Cal/